Pablo Legorreta, Royalty Pharma CEO (Patrick T. Fallon/Bloomberg via Getty Images)

Roy­al­ty Phar­ma nabs $475M mile­stone from Pfiz­er up­on mi­graine nasal spray OK

The FDA’s re­cent ap­proval of Pfiz­er’s mi­graine nasal spray was al­so good news for Roy­al­ty Phar­ma, trig­ger­ing a whop­ping $475 mil­lion mile­stone pay­ment.

Roy­al­ty first struck a deal in 2020 to of­fer Bio­haven $250 mil­lion in de­vel­op­ment fund­ing for the pro­gram, za­veg­epant, in ex­change for mile­stones and fu­ture roy­al­ties. This marks the first re­turn on that deal for Roy­al­ty, a spe­cial­ist in such pacts and an ac­cel­er­at­ed one at that, ac­cord­ing to the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.